An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 270 participants.
Also called NCT03749447
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Sponsor
- Registry
-
NCT03749447 -
2018-003253-24
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, France, Japan, Puerto Rico, Spain
- Registry status
- Terminated
Technical summary
Registry record NCT03749447. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-08 (actual); primary completion 2023-08-23 (actual). Results posted on 2024-03-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
- Acronym
- EAGLE
- Condition
- Chronic Kidney Diseases
- Condition
- Alport Syndrome
- Condition
- Autosomal Dominant Polycystic Kidney
- Intervention (Drug)
- Bardoxolone methyl
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct03749447- Content hash
fb51cf2ae601edc9ed28710b2c67cbd14d6d1a6648d14a2a3f1e9aec7fc938a3